These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 15912274)

  • 41. Imaging P-glycoprotein function in rats using [(11)C]-N-desmethyl-loperamide.
    Farwell MD; Chong DJ; Iida Y; Bae SA; Easwaramoorthy B; Ichise M
    Ann Nucl Med; 2013 Aug; 27(7):618-24. PubMed ID: 23572210
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Influence of P-glycoprotein on brain uptake of [18F]MPPF in rats.
    Passchier J; van Waarde A; Doze P; Elsinga PH; Vaalburg W
    Eur J Pharmacol; 2000 Nov; 407(3):273-80. PubMed ID: 11068023
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Human brain imaging and radiation dosimetry of 11C-N-desmethyl-loperamide, a PET radiotracer to measure the function of P-glycoprotein.
    Seneca N; Zoghbi SS; Liow JS; Kreisl W; Herscovitch P; Jenko K; Gladding RL; Taku A; Pike VW; Innis RB
    J Nucl Med; 2009 May; 50(5):807-13. PubMed ID: 19372478
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier.
    Dirson G; Fernandez C; Hindlet P; Roux F; German-Fattal M; Gimenez F; Farinotti R
    Pharm Res; 2006 Jul; 23(7):1525-32. PubMed ID: 16779703
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PET imaging to assess the impact of P-glycoprotein on pulmonary drug delivery in rats.
    Hernández-Lozano I; Mairinger S; Filip T; Sauberer M; Wanek T; Stanek J; Sake JA; Pekar T; Ehrhardt C; Langer O
    J Control Release; 2022 Feb; 342():44-52. PubMed ID: 34971693
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
    Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dynamics of multidrug resistance: P-glycoprotein analyses with positron emission tomography.
    Hendrikse NH; Vaalburg W
    Methods; 2002 Jul; 27(3):228-33. PubMed ID: 12183111
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport.
    Syvänen S; Lindhe O; Palner M; Kornum BR; Rahman O; Långström B; Knudsen GM; Hammarlund-Udenaes M
    Drug Metab Dispos; 2009 Mar; 37(3):635-43. PubMed ID: 19047468
    [TBL] [Abstract][Full Text] [Related]  

  • 49. P-Glycoprotein, not BCRP, Limits the Brain Uptake of [(18)F]Mefway in Rodent Brain.
    Choi JY; Song JS; Lee M; Cho WK; Chung J; Lyoo CH; Kim CH; Park J; Lee KC; Kim KM; Kang JH; Bae MA; Ryu YH
    Mol Imaging Biol; 2016 Apr; 18(2):267-73. PubMed ID: 26250653
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interaction of drugs with P-glycoprotein in brain capillaries.
    Jetté L; Murphy GF; Leclerc JM; Beliveau R
    Biochem Pharmacol; 1995 Nov; 50(10):1701-9. PubMed ID: 7503774
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using [(11)C]gefitinib.
    Kawamura K; Yamasaki T; Yui J; Hatori A; Konno F; Kumata K; Irie T; Fukumura T; Suzuki K; Kanno I; Zhang MR
    Nucl Med Biol; 2009 Apr; 36(3):239-46. PubMed ID: 19324269
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Imaging the impact of blood-brain barrier disruption induced by focused ultrasound on P-glycoprotein function.
    Goutal S; Novell A; Leterrier S; Breuil L; Selingue E; Gerstenmayer M; Marie S; Saubaméa B; Caillé F; Langer O; Truillet C; Larrat B; Tournier N
    J Control Release; 2023 Sep; 361():483-492. PubMed ID: 37562557
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High brain distribution of a new central nervous system drug candidate despite its P-glycoprotein-mediated efflux at the mouse blood-brain barrier.
    Taccola C; Cartot-Cotton S; Valente D; Barneoud P; Aubert C; Boutet V; Gallen F; Lochus M; Nicolic S; Dodacki A; Smirnova M; Cisternino S; Declèves X; Bourasset F
    Eur J Pharm Sci; 2018 May; 117():68-79. PubMed ID: 29427702
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of P-glycoprotein in intestinal transport versus the BBB transport of tetraphenylphosphonium.
    Swed A; Eyal S; Madar I; Zohar-Kontante H; Weiss L; Hoffman A
    Mol Pharm; 2009; 6(6):1883-90. PubMed ID: 19722701
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Screening of multidrug-resistance sensitive drugs by in situ brain perfusion in P-glycoprotein-deficient mice.
    Cisternino S; Rousselle C; Dagenais C; Scherrmann JM
    Pharm Res; 2001 Feb; 18(2):183-90. PubMed ID: 11405289
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia: a PET study with [(11)C]verapamil as a probe for P-glycoprotein function.
    de Klerk OL; Willemsen AT; Bosker FJ; Bartels AL; Hendrikse NH; den Boer JA; Dierckx RA
    Psychiatry Res; 2010 Aug; 183(2):151-6. PubMed ID: 20620031
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug binding to P-glycoprotein is inhibited in normal tissues following SDZ-PSC 833 treatment.
    Jetté L; Murphy GF; Béliveau R
    Int J Cancer; 1998 May; 76(5):729-37. PubMed ID: 9610733
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Substrates, inhibitors and activators of P-glycoprotein: candidates for radiolabeling and imaging perspectives.
    Colabufo NA; Berardi F; Perrone MG; Capparelli E; Cantore M; Inglese C; Perrone R
    Curr Top Med Chem; 2010; 10(17):1703-14. PubMed ID: 20645922
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Using PET studies of P-gp function to elucidate mechanisms underlying the disposition of drugs.
    Syvänen S; Hammarlund-Udenaes M
    Curr Top Med Chem; 2010; 10(17):1799-809. PubMed ID: 20645912
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predicting the outer boundaries of P-glycoprotein (P-gp)-based drug interactions at the human blood-brain barrier based on rat studies.
    Hsiao P; Unadkat JD
    Mol Pharm; 2014 Feb; 11(2):436-44. PubMed ID: 24364805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.